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Vascular endothelial growth factor (VEGF) is an important regulator of endothelial cell function. VEGF stimulates NO production,
proposed to be a result of phosphorylation and activation of endothelial NO synthase (eNOS) at Ser1177. Phosphorylation of eNOS at
this site also occurs after activation of AMP-activated protein kinase (AMPK) in cultured endothelial cells. We therefore determined
whether AMPK mediates VEGF-stimulated NO synthesis in endothelial cells. VEGF caused a rapid, dose-dependent stimulation of
AMPK activity, with a concomitant increase in phosphorylation of eNOS at Ser1177. Infection of endothelial cells with an adenovirus
expressing a dominant negative mutant AMPK partially inhibited both VEGF-stimulated eNOS Ser1177 phosphorylation and NO pro-
duction. VEGF-stimulated AMPK activity was completely inhibited by the Ca2+/calmodulin-dependent protein kinase kinase inhibitor,
STO-609. Stimulation of AMPK via Ca2+/calmodulin-dependent protein kinase kinase represents a novel signalling mechanism utilised
by VEGF in endothelial cells that contributes to eNOS phosphorylation and NO production.
 2007 Elsevier Inc.
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Open access under CC BY license.VEGF is a key regulator of angiogenesis, stimulating
diﬀerentiation, survival, migration, proliferation, and vas-
cular permeability of endothelial cells [1,2]. VEGF binds
to VEGF receptor tyrosine kinases, which have been
demonstrated to stimulate a diverse array of signalling
pathways, including phospholipase C (PLC)-c, phosphati-
dylinositol 3 0-kinase (PI3K), and Src [1,2].
VEGF rapidly stimulates endothelial NO synthesis
[3–5], proposed to be the result of PI3K-mediated activation
of protein kinase B (PKB, also known as Akt), which
directly phosphorylates and activates eNOS at Ser1177
[4,6]. However, VEGF-stimulated NO production has been
reported to be only partially inhibited by wortmannin, sug-
gesting that VEGF-stimulated NO production is mediated
by both PI3K/PKB and a PI3K-independent kinase [3,5,7].0006-291X 2007 Elsevier Inc.
doi:10.1016/j.bbrc.2007.01.110
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Open access under CC BY license.In addition to PKB, AMPK has been shown to phos-
phorylate and activate eNOS at Ser1177 in cultured endo-
thelial cells [8,9]. AMPK is activated by phosphorylation at
Thr172 by at least two recently characterised upstream
kinases, LKB1 and Ca2+/calmodulin-dependent protein
kinase kinase (CaMKK), especially the b isoform [10–13].
It has been proposed that the phosphorylation of AMPK
by LKB1 is triggered by metabolic stresses that increase
the intracellular AMP:ATP ratio [10,11], while phosphory-
lation and activation of AMPK by CaMKK is Ca2+-de-
pendent and independent of changes in cellular AMP
[11–13]. A key role of AMPK in the mediation of eNOS
phosphorylation has been demonstrated in response to
hypoxia, metformin, adiponectin, and shear stress [9,14–
17]. In addition, AMPK has been proposed to mediate
angiogenesis stimulated by adiponectin and hypoxia
[15,18]. AMPK, therefore, represents a candidate PI3K-in-
dependent kinase that underlies VEGF-stimulated eNOS
phosphorylation. In this study, we have investigated
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part, by AMPK in cultured human aortic endothelial cells
(HAECs).Methods
Materials. HAECs and endothelial cell culture media were obtained
from TCS Cellworks (Botolph Claydon, Bucks, UK). VEGF165 and
U73122 were supplied by Sigma (Poole, Dorset, UK). STO-609 was from
Tocris (Ellisville, MO, USA). PP1 was a generous gift from Prof. G.
Milligan, University of Glasgow, UK Rabbit anti-acetyl CoA carboxylase
(ACC) and anti-phospho-ACC Ser79 (rat ACC1 sequence) antibodies
were supplied by Upstate (Lake Placid NY, USA). Goat anti-CaMKKa
and mouse anti-CaMKKb antibodies were supplied by Santa Cruz Bio-
technology (Heidelberg, Germany). Rabbit anti-phospho-AMPK Thr172
antibodies were obtained from Cell Signaling Technology (Beverly MA,
USA). SAMS peptide (HMRSAMSGLHLVKRR) was synthesised by
Pepceuticals Ltd. (Nottingham, UK). All other reagents were from sources
described previously [9].
Cell culture. HAECs were grown in large vessel endothelial cell
medium at 37 C in 5% CO2 and used for experiments between passages 3
and 6.
Preparation of cell lysates and AMPK assay. Cells were preincubated
for 2 h at 37 C in 5 ml Krebs Ringer HEPES (KRH) buﬀer (119 mM
NaCl, 20 mM Hepes, pH 7.4, 5 mM NaHCO3, 4.7 mM KCl, 1.3 mM
CaCl2, 1.2 mM MgSO4, 1 mM KH2PO4, 0.1 mM L-arginine, 5 mM glu-
cose). After addition of test substances for various durations, lysates were
prepared, AMPK was immunoprecipitated and assayed using the SAMS
substrate peptide as described previously [9].
Adenoviruses and infection of HAECs. Control (Ad.Null) and recom-
binant adenovirus expressing dominant negative AMPK (Ad.a1DN) were
generous gifts from Dr. F. Foufelle, Centre Biome´dical des Cordeliers,
Paris. Viruses were propagated, puriﬁed, and stored as described previ-
ously [9]. HAECs were infected with 25 Pfu/cell adenovirus and cultured
for 24 h prior to experimentation. Within 24 h of infection with a GFP-
expressing virus, the majority (>95%) of HAECs expressed GFP as pre-
viously described [9].
Assay of NO production in endothelial cells. Cells cultured in 6-well
plates were preincubated for 2 h at 37 C in 0.5 ml/well KRH buﬀer at
37 C. The medium was removed and replaced with 0.4 ml fresh KRH
buﬀer in the presence or absence of VEGF (10 ng/ml), wortmannin
(100 nM) and/or L-NAME (1 mM) for 15 min. The medium was removed,
NO-speciﬁc chemiluminescence was analysed and L-NAME-sensitive NO
production calculated as described previously [9].
Immunoprecipitation of CaMKKb. HAEC lysates (100 lg) were added
to 0.5 lg mouse anti-CaMKKb antibody and mixed overnight at 4 C.
Protein G–Sepharose (20 ll of 25% slurry) was added, the volume adjusted
to 300 ll with lysis buﬀer and mixed for 4 h at 4 C. The mixture was
centrifuged (14,000g, 30 s, 4 C) and the pellet was washed three times in
lysis buﬀer.
Statistics. Unless stated otherwise, results are expressed as
means ± SD. Statistically signiﬁcant diﬀerences were determined using a
Student’s t-test, using p < 0.05 as signiﬁcant using Statview software.Fig. 1. Eﬀect of VEGF on AMPK activity and eNOS Ser1177
phosphorylation. (A) HAECs were incubated with 10 ng/ml VEGF for
various times and lysates prepared. (B) HAECs were incubated with the
indicated concentrations of VEGF for 5 min and lysates prepared. Total
AMPK was immunoprecipitated from endothelial cell lysates and assayed
for AMPK activity. In parallel experiments, lysates were subjected to
SDS–PAGE, transferred to nitrocellulose and probed with the antibodies
indicated. The intensity of the resultant bands was quantiﬁed using NIH
Image software. Representative immunoblots are shown, repeated with
similar results on three diﬀerent samples of lysates. The results are
expressed as the means ± SD % basal AMPK activity (j) or % basal
eNOS phosphorylation (s) for three independent experiments. *p < 0.01
relative to value in absence of VEGF. #p < 0.05 relative to value in
absence of VEGF.Results and discussion
To investigate whether AMPK mediates VEGF-stimu-
lated NO synthesis, we ﬁrst determined the eﬀects of phys-
iological concentrations of VEGF on AMPK activity and
eNOS Ser1177 phosphorylation in HAECs. VEGF
(10 ng/ml) elicited a transient, concomitant activation of
AMPK and eNOS phosphorylation at Ser1177, which
reached a maximum 2.8- and 3.6-fold stimulation, respec-
tively, after 5 min. Both AMPK activity and eNOS phos-phorylation rapidly returned to basal levels (Fig. 1A). In
addition, activation of AMPK and phosphorylation of
eNOS at Ser1177 by VEGF shared a similar dose-depen-
dence, such that AMPK activity and eNOS Ser1177 phos-
phorylation were stimulated maximally (2.5- and 3.6-fold,
respectively) by 10 ng/ml VEGF, a concentration at which
all further experiments were performed (Fig. 1B). Previous
studies have reported that stimulation of human umbilical
vein endothelial cells (HUVECs) with VEGF for 6 h or
bovine aortic endothelial cells (BAECs) with VEGF for
10 min was without eﬀect on phosphorylation of AMPK
at Thr172 [15,19]. These studies are in agreement with
the present study in which VEGF-stimulated AMPK activ-
ity peaked after 5 min incubation and returned to basal val-
ues within 15 min.
PI3K, PLC, and c-Src are known eﬀectors of VEGF sig-
nalling in endothelial cells and previous studies have sug-
gested that AMPK stimulation is downstream of PI3K
and c-Src activation in peroxynitrite- and metformin-treat-
ed BAECs [16,19]. In the current study, inhibition of either
PI3K or c-Src had no eﬀect on VEGF-stimulated AMPK
activity in HAECs, suggesting that neither PI3K nor c-
Src mediate VEGF-stimulated AMPK activation
(Fig. 2A). Preincubation with U73122 completely inhibited
VEGF-stimulated AMPK activity (Fig. 2), suggesting that
VEGF stimulates AMPK in a PLC-dependent manner.
Similarly, histamine has previously been reported to acti-
vate AMPK in HUVECs in a PI3K-independent, PLC-de-
pendent manner [20].
It is now apparent that CaMKKb can act as an alternate
upstream kinase to LKB1 that activates AMPK in a Ca2+-
dependent and AMP-independent manner [11–13]. A
recent report indicates that CaMKK mediates thrombin-
Fig. 2. Eﬀect of inhibitors of PLC and CaMKK on VEGF-stimulated
AMPK activity. HAECs were incubated in the presence or absence of
10 ng/ml VEGF for 5 min after preincubation with 100 nM wortmannin,
1 lM PP1, 10 lM U73122 or 25 lM STO-609 for 45 min and lysates
prepared. (A) Total AMPK was immunoprecipitated from HAEC lysates
and assayed for AMPK activity. The results are expressed as the
means ± SD % basal AMPK activity for four independent experiments.
*p < 0.01 relative to value in absence of inhibitor. (B) AMPK immuno-
precipitates were resolved by SDS–PAGE, transferred to nitrocellulose
and probed with the antibodies indicated. Representative immunoblots
are shown, repeated with similar results on four diﬀerent samples of
lysates. (C) HAEC lysates were resolved by SDS–PAGE, transferred to
nitrocellulose and probed with anti-CaMKKa antibodies. CaMKKb was
immunoprecipitated from HAEC lysate, subjected to Western blotting
and probed with anti-CaMKKb antibodies. A lysate prepared from whole
rat brain was used as a positive control. Representative immunoblots are
shown.
Fig. 3. The eﬀects of infection with Ad.a1DN on VEGF-stimulated NO
production. HAECs were infected with 25 Pfu/cell of Ad.Null or
Ad.a1DN viruses 24 h prior to experimentation. Cells were incubated in
KRH buﬀer in the presence or absence of 10 ng/ml VEGF165 and/or
100 nM wortmannin. After 15 min, medium was removed and assayed for
L-NAME-sensitive NO2 content. The data shown represent the
means ± SD NO synthesis from nine independent experiments. *p < 0.05
relative to value in Ad.Null-infected cells.
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does not underlie thrombin-stimulated eNOS Ser1177
phosphorylation [21]. As VEGF is known to stimulate
PLCc-mediated increases in intracellular Ca2+ [3,22] and
VEGF-stimulated AMPK activity is inhibited by the PLC
inhibitor U73122 (Fig. 2A), we examined whether
VEGF-stimulated AMPK activity was mediated by CaM-
KK activation by using the CaMKK inhibitor, STO-609.
Preincubation of HAECs with STO-609 reduced VEGF-
stimulated AMPK activity to basal levels (Fig. 2A), with-
out altering AICAR-stimulated AMPK activity, which is
mediated by LKB1 (data not shown). VEGF-stimulated
AMPK Thr172 phosphorylation was similarly reduced to
basal levels after preincubation with STO-609 (Fig. 2B).
STO-609 inhibits both CaMKKa and CaMKKb, yet the
expression of these isoforms in endothelial cells has not
previously been determined. Using isoform-speciﬁc anti-
CaMKK antibodies, we demonstrated expression of both
CaMKKa and CaMKKb in HAECs (Fig. 2C). These dataindicate that VEGF stimulates CaMKK via PLC-mediated
Ca2+ mobilisation, and that CaMKK, rather than LKB1 is
the upstream kinase responsible for AMPK activation in
response to VEGF in endothelial cells.
To determine the functional eﬀects of VEGF-stimulated
AMPK activity, we investigated the role of AMPK in
VEGF-stimulated eNOS phosphorylation and NO produc-
tion. Previous studies have proposed that VEGF-stimu-
lated eNOS phosphorylation at Ser1177 is mediated by
PKB [5,6], yet complete inhibition of PKB with the PI3K
inhibitor, wortmannin only partially inhibited VEGF-stim-
ulated NO production [3,5,7]. In agreement with this, pre-
incubation of HAECs with the PI3K inhibitor wortmannin
incompletely but signiﬁcantly reduced VEGF-stimulated
NO production by 65% (Fig. 3) at a concentration that
completely inhibited phosphorylation of PKB at Ser473
(data not shown). These data suggest that both PI3K/
PKB and a PI3K-independent kinase mediate VEGF-stim-
ulated NO production. Infection of HAECs with Ad.a1DN
caused a signiﬁcant (40%) reduction in VEGF-stimulated
NO production (Fig. 3). In the presence of wortmannin,
infection with Ad.a1DN signiﬁcantly reduced VEGF-stim-
ulated NO production to basal levels. Quantiﬁcation of
eNOS phosphorylation status in Ad.a1DN-infected cells
revealed VEGF-stimulated phosphorylation at Ser1177
was signiﬁcantly reduced by approximately 70% (Fig. 4).
ACC is phosphorylated by AMPK at Ser80 in ACC1
and Ser220 in ACC2 (human sequence). Using an antibody
that recognises both phosphorylated species, we demon-
strated that VEGF stimulates phosphorylation of ACC,
an eﬀect completely inhibited in HAECs infected with
Ad.a1DN (Fig. 4). These data indicate that infection with
Ad.a1DN completely inhibits VEGF-stimulated AMPK
activity. We were unable to distinguish whether the band
represented ACC1, ACC2 or both. Inhibition of ACC1/
ACC2 by phosphorylation at Ser80/Ser221 has been dem-
onstrated to inhibit fatty acid synthesis in adipose tissue
and liver whilst stimulating fatty acid oxidation in heart
and skeletal muscle [11]. Activation of AMPK with
Fig. 4. The eﬀects of infection with Ad.a1DN on VEGF-stimulated ACC
and eNOS phosphorylation. HAECs were infected with 25 Pfu/cell of
Ad.a1DN or Ad.Null 24 h prior to experimentation. Subsequently, HAEC
lysates were prepared from cells incubated in the presence or absence of
10 ng/ml VEGF, resolved by SDS–PAGE, transferred to nitrocellulose
and probed with the antibodies indicated. Speciﬁc band intensities were
quantiﬁed using NIH Image software. Representative immunoblots are
shown, repeated with similar results on four diﬀerent samples of lysates.
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HUVECs [23], so it remains possible that VEGF transient-
ly stimulates fatty acid oxidation due to AMPK-mediated
phosphorylation of ACC.
Inhibition of VEGF-stimulated eNOS Ser1177 phos-
phorylation has previously been reported in HUVECs
infected with adenoviruses expressing either dominant neg-
ative PKB or dominant negative AMPK under conditions
of hypoxia, while under normoxic conditions, dominant
negative AMPK was without any eﬀect [15]. In contrast,
we have demonstrated that AMPK contributes to VEGF-
stimulated eNOS phosphorylation and NO production
under normoxic conditions (Figs. 3 and 4). Given the
eﬀects of wortmannin and Ad.a1DN, we propose that
VEGF stimulates both PKB and AMPK-mediated phos-
phorylation of eNOS at Ser1177 under normoxic condi-
tions. Similarly, both PKB and AMPK-mediated
phosphorylation of eNOS at Ser1177 has previously been
suggested to occur in response to adiponectin in HUVECs
[18]. As incubation of HAECs with wortmannin does not
alter AMPK activity, AMPK does not act downstream of
PI3K in the response to VEGF in HAECs (Fig. 2). It
remains possible that AMPK could act upstream of PKB
in VEGF-stimulated eNOS phosphorylation, but this
seems unlikely because we have previously demonstrated
that infection with Ad.a1DN does not alter PKB phos-
phorylation in HAECs [9].
In conclusion,wehavedemonstrated for the ﬁrst time that
VEGF stimulates the transient activation of AMPK in cul-
tured endothelial cells in a PLC- and CaMKK-dependent
manner. AMPK, therefore, represents a novel component
of VEGF signalling. In addition, we propose that AMPK
represents the PI3K-independent kinase that contributes,
along with activated PKB to VEGF-stimulated eNOS
Ser1177 phosphorylation and subsequent NO production.
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